Get the Stockscreener App
0.00
100.00%
-2.38
After Hours:
2.34
2.34
+
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.38
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$114.97M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
0.00
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Filana Therapeutics (FLNA) details 2026 meeting and equity plan vote - Stock Titan
Cassava Sciences (FLNA) Financials 2026Income Statement and Balance Sheet $FLNA - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences (FLNA) Institutional Ownership 2026 $FLNA - MarketBeat
Cassava Sciences Inc Share PriceShare CFDs - FOREX.com
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 0.6%Should You Sell? - MarketBeat
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FLNA Stock Price, News & Analysis - Stock Titan
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data - GlobeNewswire
Death Cross: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Gains Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
FLNA|Cassava Sciences Ord Shs|Price:1.590|Chg%:-0.02 - TradingKey
FLNA|Cassava Sciences Ord Shs|Price:1.440|Chg%:-0.12 - TradingKey
If You Invested $1,000 in Cassava Sciences (SAVA) - Stock Titan
Trend Report: What is the dividend yield of Cassava Sciences Inc Equity Warrant2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Chart Watch: Is Cassava Sciences Inc Equity Warrant trading at a discountWeekly Market Outlook & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Leaders: Can Cassava Sciences Inc Equity Warrant maintain its current growth rate2026 Levels & Low Risk Investment Opportunities - baoquankhu1.vn
Aug Update: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestWatch List & Consistent Return Investment Signals - baoquankhu1.vn
RSI Check: What is the dividend yield of Cassava Sciences IncPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
SEC Moves To Set Up $40M Investor Fund In Cassava Case - Law360
Cassava Sciences Stock Rises 1.8% - National Today
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8%Here's What Happened - MarketBeat
RSI Check: Is Cassava Sciences Inc backed by strong institutional buying2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Dow Update: What is the dividend yield of Cassava Sciences Inc Equity WarrantInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Cassava Sciences, Inc. (FLNA) - Minichart
Energy Moves: What is Cassava Sciences Inc Equity Warrants book value per share - baoquankhu1.vn
SAVA PE Ratio & Valuation, Is SAVA Overvalued - Intellectia AI
ETF Watch: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Risk Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urg - GuruFocus
Cassava Sciences, Inc. Common Stock (FLNA) Competitors - Meyka
FOMO Trade: Does Cassava Sciences Inc Equity Warrant offer margin of safety2026 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Trading Recap: Is Cassava Sciences Inc Equity Warrant subject to activist investor interest2026 Sentiment & Daily Stock Trend Watchlist - baoquankhu1.vn
Block Trades: Does Cassava Sciences Inc Equity Warrant have pricing powerMarket Sentiment Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Filana Therapeutics Inc (FLNA-Q) Stock Price and News - The Globe and Mail
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cassava Sciences Posts Earnings, Beats Estimates - National Today
Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Total equity of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Average basic shares outstanding of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Cash Flow – BMV:FLNA - TradingView
Price to book ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Free cash flow per share of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Long term debt to total equity ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):